itp

When Maya was 2 years old, her mom Melanie took her to the pediatrician because she had fever and spots on her face. After a blood test, it was discovered that Maya's platelets were low. It wasn't leukemia, Maya has an autoimmune disorder called ITP. Melanie spoke with Ken Connors.  

In this second of two podcasts, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP. Unique considerations of the drug and surgical options are discussed. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.

Contributors:

Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota

Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.

Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.

Contributors:

Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota

Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.

Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

In this episode, Keith R. McCrae, MD; Nichola Cooper, MD; and Rachael Grace, MD, MMSc,provide expert insights on immune thrombocytopenia management, along with addressing frequently asked questions from a live CCO symposium. Topics include:

• New and emerging therapeutic options
• Special patient populations, including children
• The management of immune thrombocytopenia
• COVID-19 vaccinations and immune thrombocytopenia

Presenters:

Keith R. McCrae, MD
Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, USA

Nichola Cooper, MD
Honorary Consultant Hematologist
Hammersmith Hospital
Imperial College
London, United Kingdom

Rachael Grace, MD, MMSc
Associate Professor of Pediatrics
Harvard Medical School
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, USA

Content based on an online CME program supported by an educational grant from Amgen; Dova Pharmaceuticals, Inc.; and Sanofi Genzyme.

Advances in Immune Thrombocytopenia:
https://bit.ly/3gzykzy

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:

• Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study 
• Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITP
• New data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B 
• An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-up
• Primary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHD
• Top-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHD
• Phase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHD

Presenters:

Hanny Al-Samkari, MD
Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Sujit Sheth, MD
Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Mark A. Schroeder, MD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. 

Link to full program, including downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3tyQ9nG

#010 - Tracking preventie / Tracking prevention, ITP, Cookies etc. waarom is dit NU zo belangrijk? In het interview met Boris Schellekens (Tracedock) gaan we het hier over hebben.

Meer weten?

https://onlinemarketing.nl/tracking-prevention/

Dit zijn o.a. de onderwerpen die vandaag besproken worden:

• Wat is er op dit moment gaande omtrent tracking preventie? 
• Firefox, Safari, Microsoft Edge / IE & Google Chrome: hoe pakken ze het aan?
• Wat is het verschil tussen first-party en 'third-party' cookies?
• Wat is ITP?
• Wat is het probleem voor online marketeers? 
  • Remarketing 
  • Analytics & Conversie-tracking: Attributie
  • A/B testen & Personalisatie 
• Verschilt per browser, maar wat zijn de problemen die dit met zich meebrengt?
• Wat zijn de cijfers? 
  • 36% van de desktop gebruikers gebruiken een browser met 'tracking preventie'; 
  • 47% van alle internet gebruikers wereldwijd gebruiken een ad-blocker; 
• Wat zijn de oplossingen?

Lees meer op de website:

https://onlinemarketing.nl/tracking-prevention/

& 

https://onlinemarketing.nl/groei-door-online-marketing/

Links from Dr. Conley to Educate Yourself!

American Academy of Family Physicians

https://www.aafp.org/home.html

Medscape

https://www.medscape.com/

Dr. Conley's Clinic

http://www.echealthnet.com

Vision Board Master class

https://www.eventbrite.com/e/vision-board-masterclass-tickets-102839541838?utm_campaign=post_publish&utm_content=EBLinkEvent&utm_medium=email&utm_source=eventbrite&utm_term=fullLink&fbclid=IwAR1UdsJV3WauY_UkMPuCDc4DmIv8Er51zk0qiDRKG18Bje1bzxoPe1A2FOQ

Arise and Thrive Facebook

https://www.facebook.com/Arise-and-Thrive-103684167884118

The best way I can describe Ari Melenciano is that she is a renaissance talent. As an artist, researcher, and creative technologist, Ari is always finding new ways to express herself, speak to social issues, and find ways to use her art to enhance the lives of everyday people.

Ari talked about her residency at NYU's Interactive Telecommunications Program, which helped her create Afrotectopia, a multi-day new media arts, culture and technology festival. She also spoke about growing up around art and music, including how technology ended up being the catalyst for the work she does now. I don't want to spoil this great conversation too much -- we were both coming off of this year's Black in Design Conference, and I think you'll really feel the spirit and energy that both of us still had from the event! Ari is out here doing important and vital work, and this episode captures that perfectly. Thank you Ari for showing us a vision of an equitable future!

• Ari Melenciano's Website
• Ari Melenciano on Instagram
• Ari Melenciano on Twitter
• Afrotectopia

Facebook Design is a proud sponsor of Revision Path.

The Facebook Design community is designing for human needs at unprecedented scale. Across Facebook’s family of apps and new product platforms, multi-disciplinary teams come together to create, build and shape communication experiences in service of the essential, universal human need for connection.

To learn more, please visit facebook.design.

This episode is brought to you by Abstract: design workflow management for modern design teams.

Spend less time searching for design files and tracking down feedback, and spend more time focusing on innovation and collaboration.

Like Glitch, but for designers, Abstract is your team's version-controlled source of truth for design work. With Abstract, you can version design files, present work, request reviews, collect feedback, and give developers direct access to all specs — all from one place.

Sign your team up for a free, 30-day trial today by heading over to www.abstract.com.

Like this episode? Then subscribe to us on Apple Podcasts, Google Podcasts, SoundCloud, Spotify, or wherever you find your favorite podcasts.

Subscribe and leave us a 5-star rating and a review! Thanks so much to all of you who have already rated and reviewed us!

Revision Path is a Glitch Media Network podcast, and is produced by Maurice Cherry and edited by Brittani Brown.

You can also follow Revision Path on Facebook, Twitter, and Instagram. Come chat with us! And thanks for listening!

Powered by Simplecast. Sign up today for a 14-day free trial!

In this episode I cover thrombocytopenia.

If you want to follow along with written notes on thrombocytopenia go to https://zerotofinals.com/medicine/haematology/thrombocytopenia/ or the haematology section in the Zero to Finals medicine book.

This episode covers the definitions, types, tests, causes and treatments of thrombocytopenia. 

The audio in the episode was expertly edited by Harry Watchman.

In the Pocket is a weekly take on all things NFL. Hosted by Jay Mueller, a lifelong Arizona Cardinals (and St. Louis Cardinals) fan who now calls Melbourne, Australia home. Featuring the man from Sacramento, Steve Salisbury, Josh Silverii and James Hurley. 

Join #PocketNation on Twitter In the Pocket 

Say hello to our sponser Sports Where I Am. Use the promo code POCKETNATION to save 10% off the purchase of your tickets. 

In the Pocket is produced by Bad Producer Productions. 

See omnystudio.com/listener for privacy information.